Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

Pharmacogenetics

Volumn 11, Issue 4, 2001, Pages 341-348

  Furuta, T ^a   Shirai, N ^a   Takashima, M ^a   Xiao, F ^a   Hanai, H ^a   Nakagawa, K ^a   Sugimura, H ^a   Ohashi, K ^a   Ishizaki, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amoxicillin; CYP2C19 genotype; Extensive metabolizer; H. pylori; Poor metabolizer; Rabeprazole

Indexed keywords

AMOXICILLIN; CYTOCHROME P450 2C19; RABEPRAZOLE; UREASE;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GASTRITIS; GENOTYPE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HETEROZYGOSITY; HISTOLOGY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ALLELES; AMOXICILLIN; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PENICILLINS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTON PUMPS;

HELICOBACTER PYLORI;

EID: 0034977147     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200106000-00009     Document Type: Article

References (45)

1. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin: Influence on treatment outcome
2. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
3. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole, and pantoprazole
4. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
5. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers
6. Cancer after exposure to metronidazole
7. Rapid eradication of Helicobacter pylori infection
8. Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation
9. Proposed mechanism for metronidazole resistance in Helicobacter pylori
10. Interphenotype differences in disposition and effect on gastrin levels of omeprazole: Suitability of omeprazole as a probe for CYP2C19
11. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese
12. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans
13. Evaluation of a new selective medium for Campylobacter pylori
14. European study group on antibiotic susceptibility of Helicobacter pylori: Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori
15. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
16. In vitro anti microbial activity against H. pylori and clinical efficacy of various drugs
17. Effects of lansoprazole with or without amoxicillin on ulcer healing: Relation to eradication of Helicobacter pylori
18. Quantitative study of Helicobacter pylori by competitive PCR using synthetic DNA fragments
19. Effect of Helicobacter pylori infection on gastric juice pH
20. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
21. Effect of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
22. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
23. Helicobacter pylori infection
24. Campylobacter pylori and peptic ulcer disease
25. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents
26. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese
27. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects
28. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population
29. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study
30. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype
31. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
32. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs
33. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
34. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences
35. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial
36. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
37. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status
38. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines
39. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype
40. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor
41. Review of Helicobacter pylori eradication regimens
42. The treatment of Helicobacter pylori infection in the management of peptic ulcer diseases
43. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
44. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
45. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status